Simple
Designed to streamline workflows using familiar, standardized materials while eliminating system components that can delay or complicate setup.
VPS ENCORE® · Cardiac Graft Preservation
Introducing the future of organ preservation.
Redefining what's possible in donor heart transport.
Vascular Perfusion Solutions is advancing organ transplantation with VPS ENCORE®, a premarket cardiac perfusion system designed to extend donor heart viability up to eight hours.
• 01
Saving Organs. Saving Lives.
More than 100,000 patients are awaiting transplant. Yet standard cold storage preserves donor hearts for only up to 4 hours. As a result, only 30% of available donor hearts are transplanted.
Patients
100,000+
Awaiting transplant, nationally.
Cold Storage Ceiling
4hrs
Standard viability window for donor hearts.
Transplanted
30%
Of available donor hearts successfully placed.
Donor Heart Preservation: 4 hours → 8 hours with VP.S ENCORE®.
VPS ENCORE® is designed to extend donor heart viability, limit ischemic injury, and support more flexible timing and logistics during organ recovery and transport.
• 02
VP.S ENCORE®:
Engineered for Simplicity.
Built to address the limitations of conventional cold storage, VP.S ENCORE® represents a new approach to heart preservation technology — operating without blood or blood products, using FDA-approved perfusate and passive cooling.
VPS ENCORE® has undergone extensive preclinical evaluation, including more than 100 heart perfusions, and has received FDA Breakthrough Device Designation.
FDA Breakthrough
Bloodless
Passive Cooling
Premarket
Donor Heart Preservation Window
Live
4h
→
8h
Cold Storage Baseline
With VP.S ENCORE®
Portable
Compact, built for single-person handling, and powered by a long-lasting battery, VP.S ENCORE® supports uninterrupted preservation without relying on specialized transport or additional staff.
Reliable
Features a built-in cold storage fallback to protect the organ if circulation is interrupted, helping maintain hypothermic conditions while minimizing ischemic risk across longer distances.
• 03
Built for the Demands of Transplant Care.
Two audiences, one shared mission — expanding the window of viability and the reach of donor organs.
For Cardiac Surgeons
Machine perfusion for cardiac surgery.
The VP.S ENCORE® is being developed to address the limits of current preservation methods by supporting donor heart viability during transport and extending the window beyond standard cold storage.
Learn More
01 / 02
For OPO Teams
Transplant center solutions.
OPOs face rigorous outcome measures tied to donation rates, organ utilization, and timely transplant performance. VP.S ENCORE® supports these demands with a portable, bloodless system to help reduce transport constraints, streamline recovery logistics, and expand access to viable donor hearts.
Learn More
02 / 02
• 04
VP.S Insights.
Explore publications, scientific data, and educational resources that offer a closer look at hypothermic perfusion, organ preservation technology, and the broader VP.S ENCORE® research platform.
Featured Resource
The Organ Preservation TEMPest: The Hypothermic vs. Normothermic Turmoil in the Organ Perfusion Industry.
A closer look at the competing schools of thought shaping the next decade of perfusion science — and why bloodless hypothermic machine perfusion is emerging as the simpler, more resilient path to extended viability.
Publication
2026 · JACC
Preclinical outcomes of 100+ heart perfusions using VP.S ENCORE®
A retrospective summary of the preclinical program across multiple models and perfusion protocols.
Read Press 2026VP.S ENCORE® receives FDA Breakthrough Device Designation
Recognition from the FDA for a technology addressing an unmet need in cardiac transplantation.
Read Blog 2026Why passive cooling matters in extended transport
The engineering rationale for designing out active refrigeration — and what it means in the field.
Read• 04a
Academic Collaborations and Research Initiatives.
Vascular Perfusion Solutions is advancing research initiatives in collaboration with leading cardiac centers, government institutions, and more. Ongoing work includes organ preservation science, pediatric heart preservation, kidney preservation, gene delivery during perfusion, and vascularized composite tissue preservation.
Duke
UT Health San Antonio
Texas Heart Institute
DOD
ARPA-H + Wyss Institute
siRNA Research Funding
Duke
UT Health San Antonio
Texas Heart Institute
DOD
ARPA-H + Wyss Institute
siRNA Research Funding
• 05
About Vascular Perfusion Solutions.
Vascular Perfusion Solutions is a Texas-based MedTech company focused on advancing cardiac graft preservation through simplified hypothermic machine perfusion technology. The company takes a data-driven, evidence-based approach to research and development, working closely with leading scientists, engineers, and industry advisors to rigorously evaluate and refine its technology.
- FoundedSan Antonio, Texas
- StagePremarket · FDA Breakthrough
- FlagshipVP.S ENCORE®
- MechanismHypothermic machine perfusion
- Preclinical100+ heart perfusions
Its flagship system, VPS ENCORE®, reflects this commitment to scientific integrity and practical innovation in cardiac transplantation.